EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European ...

The FDA has approved Imfinzi (durvalumab) as neoadjuvant and adjuvant treatment in patients with muscle-invasive bladder cancer.

Approval of Imfinzi marks the first and only perioperative immunotherapy indicated for muscle-invasive bladder cancer.